Table 5

Interactions between nonsteroidal anti-inflammatory drug (NSAID) use and MDR1, COX-2 and BCRP polymorphisms.

Polymorphism

Ncase/Nsub-cohort

IRRa (95% CI)

IRRb (95% CI)

p-valuec

NSAIDd

NSAIDd

NSAIDd

NO

YES

NO

YES

NO

YES


MDR1 C3435T

CC

41/79

32/39

1.00

-

2.21

(1.17-4.17)

1.00

-

2.34

(1.22-4.48)

0.001

CT and TT

204/449

82/198

0.92

(0.60-1.41)

0.83

(0.52-1.33)

0.99

(0.63-1.54)

0.86

(0.53-1.39)

MDR1 G-rs 3789243-A

GG

54/160

27/64

1.00

-

1.35

(0.77-2.35)

1.00

-

1.31

(0.74-2.32)

0.26

GA and AA

191/368

87/173

1.65

(1.15-2.38)

1.65

(1.09-2.49)

1.66

(1.15-2.41)

1.61

(1.06-2.46)

COX-2 G-765C

GG

180/397

87/169

1.00

-

1.22

(0.89-1.69)

1.00

-

1.20

(0.86-1.67)

0.06

CG and CC

65/131

27/68

1.22

(0.86-1.75)

0.93

(0.57-1.51)

1.23

(0.85-1.78)

0.90

(0.54-1.48)

COX-2 A-1195G

AA

156/329

74/153

1.00

-

1.05

(0.75-1.48)

1.00

-

0.99

(0.69-1.41)

0.46

AG and GG

89/199

40/84

0.91

(0.66-1.27)

1.04

(0.67-1.60)

0.88

(0.63-1.23)

1.04

(0.67-1.61)

COX-2 T8473C

TT

94/222

53/93

1.00

-

1.42

(0.92-2.18)

1.00

-

1.38

(0.89-2.14)

0.04

CT and CC

151/306

61/144

1.23

(0.89-1.70)

1.09

(0.73-1.62)

1.22

(0.87-1.69)

1.05

(0.70-1.58)

BCRP C421A

CC

199/414

97/178

1.00

-

1.20

(0.88-1.63)

1.00

-

1.18

(0.85-1.62)

0.09

CA and AA

46/114

17/59

0.86

(0.58-1.27)

0.62

(0.35-1.10)

0.86

(0.57-1.29)

0.60

(0.33-1.08)


aCrude (adjusted for age and sex).

bAdjusted for status of HRT (women only), smoking status, alcohol, dietary fibre, red meat and BMI.

cp-value for interaction for the fully adjusted risk estimates.

dStudy subjects were classified according to use of "any NSAID" (≥ 2 pills per month during one year) at baseline

Andersen et al. BMC Cancer 2009 9:407   doi:10.1186/1471-2407-9-407

Open Data